Follow on Google News
News By Tag
News By Place
Follow on Google News
United Investment Limited - Can this help the stock's fortunes?
Novavax Inc. (NVAX) is a beaten-down COVID company, with shares down 85% since the beginning of the year.
However, the organization just received fantastic news. The Food and Drug Administration (FDA) approved its vaccination for Emergency Use Authorization (EUA) as an adult booster. And the Centres for Disease Control and Prevention (CDC) has given adults 18 and above the go-ahead to use it as a booster, even if they've already gotten Moderna or Pfizer injections as their initial dosage.
NVAX has a big possibility to reach a large section of the market. According to CDC data, over half of persons who have had both of their original COVID-19 vaccination doses have yet to receive a booster. Because the CDC has approved of mixing and matching, NVAX is not limited to persons who have received its vaccine.
However, there are certain limitations to the authorisation. According to the FDA, the injection should be given to persons who are unable to obtain an authorized mRNA-based bivalent COVID-19 booster or whose mRNA booster is not "clinically acceptable" for them. However, NVAX's booster may also be available to adults who opt to have the injection "since they would not otherwise obtain a booster dose of a COVID-19 vaccination."
The COVID injection from NVAX is a more conventional, protein-based vaccination, as opposed to the relatively recent mRNA technology used by vaccines from Pfizer and Moderna. NVAX might be a welcome option for folks who prefer a more conventional injection or who had negative side effects with mRNA vaccinations. However, estimating how much demand this reflects in light of the constraints is difficult, if not impossible.
Novavax received an EUA earlier this year for its vaccine as a main two-dose series for those who have not yet been immunized. With 68% of the U.S. population completely vaccinated,
Although demand for vaccinations and boosters may decline as the economy returns to normal, Novavax might potentially increase the popularity of their vaccine by offering a cheaper price than competitors now that the market is shifting.
The private sector, rather than the government, will drive demand for COVID-19 vaccinations and boosters next year. The government is running out of COVID-19 vaccinations, and due to a shortage of finance, it will no longer be stockpiling them.
At United Investment (https://unitedinvest-